bioMerieux (OTCMKTS:BMXMF) Share Price Crosses Below Fifty Day Moving Average - Time to Sell?

Key Points

• bioMerieux shares fell below their 50-day moving average of $143.95, trading at a low of $140.25, indicating a potential bearish trend.
• Royal Bank of Canada downgraded bioMerieux from a "moderate buy" to a "hold" rating, reflecting a cautious outlook from analysts.
• The company's debt-to-equity ratio is notably low at 0.08, suggesting strong financial stability despite recent stock performance fluctuations.

Shares of bioMerieux (OTCMKTS:BMXMF - Get Free Report) passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $143.95 and traded as low as $140.25. bioMerieux shares last traded at $140.25, with a volume of 50 shares traded.

Analyst Ratings Changes

Separately, Royal Bank Of Canada cut shares of bioMerieux from a "moderate buy" rating to a "hold" rating in a report on Wednesday, May 7th. One research analyst has rated the stock with a Hold rating, According to MarketBeat.com, bioMerieux currently has an average rating of "Hold".

bioMerieux Price Performance

The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.29 and a current ratio of 2.20. The business has a 50-day moving average price of $143.86 and a 200 day moving average price of $133.88.

About bioMerieux

bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.